Previously, patients with nonmetastatic castration-resistant prostate cancer (nmCRPRC) and the clinicians treating them had no therapeutic options to delay disease progression. Now there are two new non-steroidal anti-androgens, apalutamide and enzalutamide, on the horizon. Speaking from the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Neal Shore, MD, FACS, of Carolina Urologic Research Center, Myrtle Beach, SC, discusses the Phase III trials of these drugs, SPARTAN (NCT01946204) and PROSPER (NCT02003924), and forecasts how he expects the results of these to impact clinical practice.
How will new NSAAs impact clinical practice in prostate cancer?
